Abhishek Jamanadas Malaviya

Abhishek Jamanadas Malaviya

Active Director Whole-Time Director DIN 05347389
DIN 05347389 First appointment Oct 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Oct 2012
Shareholding value •••• Premium profile

About Abhishek Jamanadas Malaviya

Data last updated:

Abhishek Jamanadas Malaviya is a Whole-Time Director at Sunrise Remedies Private Limited (since 2018), Director at Yogi International Private Limited (since 2013) and Nominee Director at Amster Lifesciences Private Limited (since 2025), and holds 1 more current directorship. The companies operate in Pharma and Research & Development. The 2 current companies with reported revenue have a combined latest revenue of ₹42.51 Cr; the largest is Sunrise Remedies Private Limited at ₹40.84 Cr (FY 2024). Earlier, Abhishek Jamanadas Malaviya was a Director at Y.P. Healthcare Private Limited (from 2012).

DIN 05347389
Primary Designation Whole-Time Director
Industry Pharma
First Appointment 10 Oct 2012
Oldest Company Age 30 yrs
Largest company Sunrise Remedies Private Limited · ₹40.84 Cr (FY 2024)
Combined revenue ₹42.51 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sunrise Remedies Private Limited U24231GJ1996PTC028804
Whole-Time Director10 Dec 20181996₹40.84 Cr (FY 2024)Active
Yogi International Private Limited U51397GJ2013PTC077712
Director02 Dec 20132013₹1.68 Cr (FY 2025)Active
Amster Lifesciences Private Limited U46497GJ2025PTC165058
Nominee Director14 Jul 20252025Active
Sunrise Pharmachem Private Limited U73100GJ2020PTC114615
Director14 Jul 20202020Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Y.P. Healthcare Private Limited U24232GJ2012PTC072269
Director10 Oct 20122012Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Sunrise Remedies Private Limited
Y.P. Healthcare Private Limited
Yogi International Private Limited
Sunrise Pharmachem Private Limited
Premium access

Shareholding and investment profile for Abhishek Jamanadas Malaviya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abhishek Jamanadas Malaviya

Abhishek Jamanadas Malaviya currently holds 4 directorships: Sunrise Remedies Private Limited (Whole-Time Director, since 10 Dec 2018, revenue ₹40.84 Cr (FY 2024)); Yogi International Private Limited (Director, since 02 Dec 2013, revenue ₹1.68 Cr (FY 2025)); Amster Lifesciences Private Limited (Nominee Director, since 14 Jul 2025); Sunrise Pharmachem Private Limited (Director, since 14 Jul 2020).

Abhishek Jamanadas Malaviya was first appointed on 10 Oct 2012 as Director at Y.P. Healthcare Private Limited. The most recent appointment on record is 14 Jul 2025 at Amster Lifesciences Private Limited.

The 2 current companies of Abhishek Jamanadas Malaviya that report revenue have a combined latest revenue of ₹42.51 Cr: Sunrise Remedies Private Limited ₹40.84 Cr (FY 2024); Yogi International Private Limited ₹1.68 Cr (FY 2025).

Abhishek Jamanadas Malaviya held 1 earlier board appointment: Y.P. Healthcare Private Limited (Director, from 10 Oct 2012).

The current boards of Abhishek Jamanadas Malaviya's companies include Jamnadas Malaviya (Sunrise Remedies Private Limited), Dilipkumar Hanvantraj Gulechha (Amster Lifesciences Private Limited), Ashwinbhai Kantilal Suvagiya (Sunrise Pharmachem Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available